Digital Library
Close Browse articles from a journal
     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             60 results found
no title author magazine year volume issue page(s) type
1 Adding radiotherapy to chemotherapy in advanced NSCLC Brower, Vicki
2017
18 11 p. e645
article
2 Adequate SIRT activity dose is as important as adequate chemotherapy dose Braat, Arthur J A T
2017
18 11 p. e636
article
3 Adequate SIRT activity dose is as important as adequate chemotherapy dose – Authors' reply Sharma, Ricky A
2017
18 11 p. e637
article
4 Adjuvant zoledronic acid to treat breast cancer: not for all Costa, Luís
2017
18 11 p. 1437-1439
article
5 An action plan for cancer control in the USA Collingridge, David
2017
18 11 p. e619
article
6 Antibody-drug conjugates: can the payload improve activity in HER2 expressing cancers? Shah, Manish A
2017
18 11 p. 1433-1434
article
7 Cancer, checkpoint inhibitors, and confusion Fernandes, Michael
2017
18 11 p. e632
article
8 Cancer control in Africa: infrastructure, not philanthropy The Lancet Oncology,
2017
18 11 p. 1423
article
9 Cancer in Tinsel Town Lucas, Catherine
2017
18 11 p. 1443
article
10 Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS Kim, Sung-Bae
2017
18 11 p. e638
article
11 Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers Ahn, Daniel H
2017
18 11 p. 1427-1428
article
12 CONVERTed or not: what are the barriers to implementing the evidence? Katz, Matthew S
2017
18 11 p. e627
article
13 CONVERTed or not: what are the barriers to implementing the evidence? – Author's reply Faivre-Finn, Corinne
2017
18 11 p. e628
article
14 Copanlisib in heavily pretreated indolent lymphoma Das, Manjulika
2017
18 11 p. e650
article
15 Correction to Lancet Oncol 2017; 18: 1502–11 2017
18 11 p. e642
article
16 Correction to Lancet Oncol 2017; 18: e315–29 2017
18 11 p. e642
article
17 Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial Beer, Tomasz M
2017
18 11 p. 1532-1542
article
18 Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Wu, Yi-Long
2017
18 11 p. 1454-1466
article
19 Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial Coleman, Robert
2017
18 11 p. 1543-1552
article
20 Effect of patient choice and hospital competition on service configuration and technology adoption within cancer surgery: a national, population-based study Aggarwal, Ajay
2017
18 11 p. 1445-1453
article
21 Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial Tjan-Heijnen, Vivianne C G
2017
18 11 p. 1502-1511
article
22 Extended adjuvant therapy: the role of subset analyses Pritchard, Kathleen I
2017
18 11 p. 1431-1433
article
23 First-line obinutuzumab for follicular lymphoma Baker, Holly
2017
18 11 p. e648
article
24 First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study Balar, Arjun V
2017
18 11 p. 1483-1492
article
25 Future cancer research priorities in the USA: a Lancet Oncology Commission Jaffee, Elizabeth M
2017
18 11 p. e653-e706
article
26 Implementing the Cancer Moonshot and beyond Lowy, Doug R
2017
18 11 p. e622-e623
article
27 Inpatient palliative care during transplantation Gunjur, Ashray
2017
18 11 p. e644
article
28 Insulin analog linked to breast cancer risk Gourd, Elizabeth
2017
18 11 p. e646
article
29 Is competition bad for our health(care)? We simply don't know Chalkidou, Kalipso
2017
18 11 p. 1424-1425
article
30 Lung cancer screening and its continuous risk assessment de Koning, Harry J
2017
18 11 p. 1434-1436
article
31 Maintenance rituximab in mantle-cell lymphoma Burki, Talha Khan
2017
18 11 p. e647
article
32 Mapping a path for cancer precision medicine Price, Douglas K
2017
18 11 p. 1444
article
33 Moving toward a precision medicine approach in metastatic castration-resistant prostate cancer Aggarwal, Rahul
2017
18 11 p. 1436-1437
article
34 Neo-adjuvant chemotherapy alone or with regional hyperthermia for soft-tissue sarcoma Roussakow, Sergey
2017
18 11 p. e629
article
35 Neo-adjuvant chemotherapy alone or with regional hyperthermia for soft-tissue sarcoma – Authors' reply Issels, Rolf D
2017
18 11 p. e630
article
36 Neoadjuvant chemotherapy in oesophageal adenocarcinoma van Laarhoven, Hanneke W M
2017
18 11 p. e639
article
37 Neoadjuvant chemotherapy in oesophageal adenocarcinoma Fornaro, Lorenzo
2017
18 11 p. e640
article
38 Neoadjuvant chemotherapy in oesophageal adenocarcinoma – Authors' reply Alderson, Derek
2017
18 11 p. e641
article
39 New option for cisplatin-ineligible urothelial cancer Dreicer, Robert
2017
18 11 p. 1428-1430
article
40 Oncolytic virus therapy in advanced melanoma Gourd, Elizabeth
2017
18 11 p. e649
article
41 One for sorrow, two for joy Swain, Kelley
2017
18 11 p. 1442-1443
article
42 Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study Tammemagi, Martin C
2017
18 11 p. 1523-1531
article
43 Patients, data, and progress in cancer care Chrischilles, Elizabeth A
2017
18 11 p. e624-e625
article
44 PD-1 inhibition in bone sarcoma and soft-tissue sarcoma Mir, Olivier
2017
18 11 p. 1430-1431
article
45 Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial Tawbi, Hussein A
2017
18 11 p. 1493-1501
article
46 Physical fitness and cancer Estévez-López, Fernando
2017
18 11 p. e631
article
47 Priorities for cancer research in the USA Simon, Gregory C
2017
18 11 p. e620-e621
article
48 Pyrotinib shows activity in metastatic breast cancer Gourd, Elizabeth
2017
18 11 p. e643
article
49 Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial Catenacci, Daniel V T
2017
18 11 p. 1467-1482
article
50 Rising cancer drug costs in the USA Burki, Talha Khan
2017
18 11 p. e652
article
51 Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study Doi, Toshihiko
2017
18 11 p. 1512-1522
article
52 The Cancer Moonshot from a European perspective Ciardiello, Fortunato
2017
18 11 p. e626
article
53 The Purple Drug Guide Kinsey, Caroline
2017
18 11 p. 1441-1442
article
54 49th SIOP Congress Landman, Allison
2017
18 11 p. 1440
article
55 Timing of androgen-deprivation therapy in prostate cancer Del Priore, Giuseppe
2017
18 11 p. e633
article
56 Timing of androgen-deprivation therapy in prostate cancer Nandagopal, Lakshminarayanan
2017
18 11 p. e634
article
57 Timing of androgen-deprivation therapy in prostate cancer – Author's reply Duchesne, Gillian M
2017
18 11 p. e635
article
58 Treatment choice in EGFR-mutant non-small-cell lung cancer Brueckl, Wolfgang M
2017
18 11 p. 1425-1426
article
59 UK radiologist staffing crisis reaches critical levels Gourd, Elizabeth
2017
18 11 p. e651
article
60 What Cancer Taught Me Denny, Victoria
2017
18 11 p. 1441
article
                             60 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands